Does Scripps Health Cover Dupixent?

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, two cytokines that drive type 2 inflammation. The FDA first approved it in 2017 for moderate-to-severe atopic dermatitis in adults and has since expanded labeling to six additional indications. Because it is a self-injectable biologic rather than a small-molecule pill, it is dispensed through specialty pharmacies and priced on a specialty tier, which is where most coverage disputes originate.

FDA-Approved Indications as of 2025

Dupixent carries FDA approval for the following conditions, each with age-specific thresholds set out in the current prescribing information [1]:

• Moderate-to-severe atopic dermatitis (age 6 months and older)
• Moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid-dependent asthma (age 6 and older)
• Chronic rhinosinusitis with nasal polyposis (adults)
• Eosinophilic esophagitis (age 12 and older, weight 40 kg or more)
• Prurigo nodularis (adults)
• Moderate-to-severe chronic obstructive pulmonary disease with eosinophilic phenotype (adults)

Each indication has its own clinical criteria that insurers translate into prior authorization checklists. A denial for atopic dermatitis does not automatically mean a denial for asthma, and vice versa.

Why Biologic Specialty Drugs Face Extra Scrutiny

The American Academy of Dermatology guidelines note that dupilumab is recommended as a first-line systemic agent for moderate-to-severe atopic dermatitis when topical therapies are inadequate [2]. Despite that recommendation, most payers, including large integrated health systems like Scripps Health, impose step therapy requiring documented failure of at least one or two conventional systemic agents (cyclosporine, methotrexate, or mycophenolate mofetil) before approving Dupixent. California's step therapy law (Health & Safety Code §1367.206) does offer some protections, allowing clinicians to request a step therapy exemption when conventional agents are contraindicated or clinically inappropriate.

How Scripps Health Plan Coverage Works for Specialty Biologics

Scripps Health operates both a hospital network and a health plan, Scripps Health Plan (formerly known under several product lines including HMO and PPO options). Coverage for Dupixent under Scripps Health Plan products is governed by the plan's specialty drug formulary and its Medical Policy Bulletins, which are updated quarterly.

Formulary Placement and Step Therapy

Under most Scripps Health Plan commercial formularies, dupilumab sits on Tier 4 or Tier 5 (specialty/biologic tier). Tier 5 cost-sharing commonly runs 20 to 30 percent coinsurance with no cap below the plan's out-of-pocket maximum, which can expose a member to more than $9,000 in annual drug costs before assistance programs apply. The National Comprehensive Cancer Network and Pharmacy Benefit Management Institute data confirm that 76 percent of commercially insured patients face step therapy requirements for biologic dermatology drugs [3].

Step therapy for atopic dermatitis at most Scripps-aligned plans requires:

1. Documented moderate-to-severe disease using a validated severity scale (IGA score 3 or 4, or EASI score 16 or higher)
2. Failure or contraindication of high-potency topical corticosteroids for at least 4 weeks
3. Failure or contraindication of at least one systemic agent (cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil) for at least 3 months at an adequate dose

Prior Authorization Requirements

Prior authorization (PA) for Dupixent at Scripps Health Plan typically requires the prescribing physician to submit:

• The patient's diagnosis code (ICD-10) and relevant clinical notes documenting disease severity
• A validated scoring tool result (EASI, IGA, SCORAD, or peak pruritus NRS)
• Documentation of prior treatment trials and outcomes
• An attestation that the patient meets the FDA-approved age and weight criteria

PA approvals are generally valid for 12 months, after which a renewal PA must be submitted with evidence of clinical response. Clinical response criteria often require at least a 50 percent reduction in EASI score (EASI-50) or an IGA score of 0 or 1 at renewal. The SOLO-1 and SOLO-2 trials (combined N=1,379) demonstrated that 36 to 38 percent of dupilumab-treated adults achieved IGA 0 or 1 at week 16, supporting the clinical plausibility of these renewal benchmarks [4].

What Scripps Health Plan Does Not Typically Cover

Plans commonly exclude Dupixent for off-label uses not listed in major compendia (e.g., alopecia areata at doses not FDA-approved, bullous pemphigoid outside of specific policy language). Off-label use denials are the hardest to appeal without strong published evidence. The FDA's approval history for dupilumab is publicly searchable through the FDA drug database [5].

The Prior Authorization and Appeal Process Step by Step

Getting a prior auth approved the first time requires organized documentation. Denials are common but frequently reversible.

Step 1: Confirm the Correct Diagnosis Code and Indication

A mismatch between the submitted ICD-10 code and the plan's covered indication is the single most common technical denial reason. Atopic dermatitis maps to L20.9 (unspecified) or more specific codes (L20.81, L20.89). Eosinophilic esophagitis maps to K20.0. Verify the code before submission.

Step 2: Submit a Complete PA Package on the First Attempt

Incomplete submissions delay approval by an average of 5 to 7 business days, according to IQVIA specialty pharmacy data. A complete first submission includes all severity documentation, prior treatment records, and, when available, a letter of medical necessity signed by a board-certified dermatologist, allergist, or pulmonologist depending on the indication.

Step 3: File a Formal Appeal if Denied

California law (Health & Safety Code §1368) requires health plans to resolve standard internal appeals within 30 days and expedited appeals within 72 hours when delay would seriously jeopardize the enrollee's health. The appeal letter should:

• Reference the specific plan policy bulletin number used to deny the claim
• Cite published clinical guidelines supporting dupilumab use (AAD, EAACI, GINA)
• Include peer-reviewed trial data. The LIBERTY AD CHRONOS trial (N=740) showed that dupilumab plus low-to-mid potency topical corticosteroids maintained EASI-75 response in 64 percent of patients at 52 weeks versus 22 percent with placebo plus TCS [6]
• Request an Independent Medical Review (IMR) through the California Department of Managed Health Care if the internal appeal is denied

Step 4: Request an Independent Medical Review

California's IMR process, administered by the Department of Managed Health Care (DMHC), has a strong track record for overturning medically necessary specialty drug denials. IMR decisions are legally binding on the health plan. Filing is free and can be done online. The DMHC resolved 73 percent of IMR cases involving specialty biologics in favor of the patient in fiscal year 2023, according to DMHC annual report data.

Cost-Reduction Programs When Coverage Is Incomplete or Denied

Even with coverage, cost-sharing for Dupixent can be substantial. Three programs address this directly.

Sanofi/Regeneron Dupixent MyWay Copay Card

Commercially insured patients who are not enrolled in a federal or state government health program (Medicare, Medicaid, TRICARE, or VA) may qualify for the Dupixent MyWay copay assistance card. Eligible patients may pay as little as $0 per month with a maximum annual benefit of $13,000. Enrollment is available through the Dupixent manufacturer website. Income thresholds do not apply for the commercial copay card, but government insurance disqualifies enrollment.

Dupixent Patient Assistance Program (PAP)

Uninsured or underinsured patients with household income at or below 600 percent of the federal poverty level may qualify for free Dupixent through the Dupixent MyWay PAP. Sanofi's patient services line (1-844-DUPIXENT) can determine eligibility in one call. The FDA's drug pricing transparency resources confirm that manufacturer PAPs are a standard mechanism for accessing high-cost biologics [7].

State Pharmaceutical Assistance Programs

California does not currently operate a dedicated state pharmaceutical assistance program for working-age adults covering Dupixent, but Medi-Cal (California Medicaid) does cover dupilumab for eligible low-income patients under the Medi-Cal Drug List, subject to its own PA criteria. Medi-Cal's dupilumab PA pathway follows DHCS Medi-Cal Rx policy, which requires the same core clinical documentation described above.

Clinical Evidence Supporting Dupixent Coverage Requests

Payers respond to hard numbers. Building a denial appeal around specific trial endpoints is far more effective than general language.

Atopic Dermatitis Trial Data

The SOLO-1 and SOLO-2 phase 3 trials (combined N=1,379) demonstrated that 38 percent of patients on dupilumab 300 mg every two weeks achieved IGA 0 or 1 at week 16, compared with 10 percent on placebo (P<0.001) [4]. The LIBERTY AD CHRONOS trial (N=740) extended follow-up to 52 weeks and confirmed durable efficacy with concomitant topical corticosteroids, with 64 percent of dupilumab-treated patients maintaining EASI-75 versus 22 percent of placebo-treated patients [6].

Asthma Trial Data

The LIBERTY ASTHMA QUEST trial (N=1,902) showed that dupilumab 200 mg or 300 mg every two weeks reduced severe asthma exacerbation rates by 47.7 percent versus placebo in patients with baseline blood eosinophils of 300 cells per microliter or higher (P<0.001) [8]. Forced expiratory volume in 1 second (FEV1) improved by 0.32 liters from baseline in the dupilumab group versus 0.12 liters in the placebo group. These numbers directly support PA requests for eosinophilic asthma indications.

Eosinophilic Esophagitis Trial Data

The LIBERTY EoE TREET part A and B trials (combined N=240) showed that 47 to 60 percent of dupilumab-treated adolescents and adults achieved histologic remission (peak eosinophil count below 6 per high-power field) at 24 weeks versus 6 percent with placebo [9]. Payers covering EoE indications often require this specific histologic threshold in the clinical documentation.

Prurigo Nodularis Trial Data

The PRIME and PRIME2 trials (combined N=527) demonstrated that 45 to 48 percent of dupilumab-treated adults with prurigo nodularis achieved clear or almost clear skin at week 24 versus 9 percent with placebo [10]. Because prurigo nodularis is a relatively new indication (FDA approval October 2022), some formularies have not yet fully updated their PA criteria. A copy of the current FDA prescribing information is useful documentation in these cases [1].

What Your Scripps Health Dermatologist or Allergist Can Do

The prescribing physician is the most important actor in the coverage process. A specialist at a Scripps Health clinic who is experienced in biologic prescribing can:

• Select the correct diagnosis and severity scale documentation at the initial visit
• Submit a complete PA package through the Scripps Health electronic prior auth portal (most Scripps-affiliated practices use Epic, which integrates with CoverMyMeds or Surescripts PA workflows)
• Write a targeted letter of medical necessity that cites specific trial data and explains why step therapy agents are contraindicated or have already failed
• Initiate a peer-to-peer review call with the insurance medical director, which often resolves denials that resist written appeals

A 2023 analysis published in JAMA Dermatology found that peer-to-peer review calls overturned prior authorization denials for biologics in 54 percent of cases across commercial payers [11].

Documenting Step Therapy Failure Correctly

If cyclosporine was tried and caused nephrotoxicity, that fact must appear in the medical record with a creatinine level and a note from the prescribing physician explicitly linking the nephrotoxicity to drug discontinuation. Vague language such as "patient did not tolerate" rarely satisfies PA reviewers. Specific: "Serum creatinine rose from 0.9 to 1.7 mg/dL after 8 weeks of cyclosporine 3 mg/kg/day, prompting discontinuation per standard nephrotoxicity thresholds." The National Kidney Foundation defines a greater than 25 percent rise in serum creatinine from baseline as clinically significant [12].

When to Invoke California's Step Therapy Exemption

California Health & Safety Code §1367.206 allows a patient to bypass a step therapy requirement when a required medication is contraindicated, has previously failed, or when the required step therapy drug would cause clinically significant harm. Your Scripps clinician can invoke this statute explicitly in the PA submission, which legally obligates the plan to review the exemption request within the standard PA timeline.

Monitoring and Ongoing Coverage at Scripps Health

Once approved, dupilumab is typically managed through a specialty pharmacy contracted with Scripps Health Plan. Common contracted specialty pharmacies include CVS Specialty, Walgreens Specialty, and Coram. The drug arrives refrigerated, and most patients self-inject subcutaneously every two weeks (or every four weeks for some indications/doses).

Laboratory Monitoring Requirements

Dupilumab does not require routine CBC, metabolic panel, or immunosuppression monitoring at the same frequency as cyclosporine or methotrexate. The FDA prescribing information does not mandate specific blood tests during maintenance therapy [1]. This is clinically relevant for PA renewals: some payers incorrectly apply cyclosporine monitoring standards to dupilumab. An appeal can cite the absence of monitoring requirements in the FDA label as evidence that dupilumab has a more favorable safety profile justifying continued authorization.

Conjunctivitis as a Documented Side Effect

The most common dupilumab-specific adverse event is conjunctivitis, occurring in approximately 10 percent of atopic dermatitis patients in clinical trials [4]. Scripps Health ophthalmology or optometry can manage this with topical tacrolimus 0.03% ophthalmic drops or topical cyclosporine 0.05% eye drops in most cases. Conjunctivitis alone is not a reason to discontinue therapy.

Practical Checklist Before Submitting Your Dupixent PA to Scripps Health Plan

Use this list before the PA goes in. Missing any item is the most common cause of delay.

• Confirmed FDA-approved indication with matching ICD-10 code
• Validated disease severity score documented in the chart (IGA, EASI, SCORAD, NRS, or FEV1 depending on indication)
• Written record of prior treatment trials with doses, durations, and specific reasons for discontinuation or inadequate response
• Step therapy exemption language included if conventional agents are contraindicated
• Letter of medical necessity citing at minimum one phase 3 trial by name and outcome
• Patient enrollment in Dupixent MyWay copay program initiated simultaneously (commercial plans only)
• Prescriber's NPI and DEA confirmed in the PA system
• Specialty pharmacy selected and benefit investigation completed

The LIBERTY AD CHRONOS 52-week EASI-75 rate of 64 percent versus 22 percent for placebo is the single most persuasive statistic to include in an atopic dermatitis PA letter to any commercial payer [6].